Whistleblower says Cephalon ignored DoJ pact to push off-label uses FiercePharma The suit says the essence of Cephalon's scheme was to illegally promote its leukemia treatment Treanda in combination with rituximab for front-line use against indolent non-Hodgkin's lymphoma, a use for which the FDA had not approved it. It alleges ... |
